Identification of new disease predisposition genes with chip-based technologies typically requires extensive financial and sample resources. We have recently shown that combining peripheral blood genome and transcriptome (BGT) information in highly selected materials can be a successful low-cost approach to unravelling dominant tumour susceptibility. In this study, we extended our investigations to recessively inherited tumour predisposition, and identified a homozygous germline mutation in the damage-specific DNA binding protein 2 (DDB2) gene in a patient with several facial tumours, for which doctors had been unable to provide a diagnosis. Our results provide proof of principle that BGT is a powerful approach for both dominant and recessive genes. In addition to tumour susceptibility, the method may be useful in characterising genetic defects underlying other disease phenotypes.
- Xeroderma igmentosum
- complementation group E
- expression profiling
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Ethics approval: Patient information and samples were obtained with full informed consent. The study was approved by the appropriate ethics review committee of the Hospital District of Helsinki and Uusimaa.
Funding: This work has been financially supported by the Academy of Finland (Center of Excellence in Translational Genome-Scale Biology 2006–2010, grant 212901 for PV) and Finnish Cultural Foundation.
Competing interests: None.
- blood genome and transcriptome
- damage-specific DNA binding protein 2
- nucleotide excision repair
- unscheduled DNA synthesis
- xeroderma pigmentosum